Lupin tops world pharma and all Indian sectors in S&P ESG rankings
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
Nadda underlined that India’s policy framework is aligned with this transformation
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
If approved, DTX401 would be the first treatment to address the disease at its root cause
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Subscribe To Our Newsletter & Stay Updated